Recombinant Anti-IL12 x Anti-IL18 Bispecific Antibody (Tandem scFv) is designed to be expressed as a scFv from an anti-IL12 antibody variable domains fused with a scFv from an anti-IL18 antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can bind and inactivate two ligands simultaneously. It is designed for the research of Arthritis therapy.